[Nocturnal use of pirenzepine by a group of insulin dependent juvenile diabetics].
Different studies have shown an elevation of GH levels in insulin-dependent diabetic adults and its modification after pirenzepine administration. We have studied nocturnal GH secretion (NIGHS) and fructosamine levels before and after one month of administering a nocturnal dose of pirenzepine [Gastrozepin (R.) 0.6 mg/kg] in a group of eight young insulin-dependent diabetics, 6 males and 2 females. The ages of the subjects ranged between 12 and 17 years with a mean age of 15.28 years. The most important findings were: 1) The NIGHS was not modified by pirenzepine administration, 10.88 +/- 3.81 ng/ml/min vs 11.25 +/- 7.90 ng/ml/min, p greater than 0.05. However, two patients showed a clear decrease in their G.H. levels. 2) Plasma fructosamine levels were also unaffected, 409 +/- 101 mmol/l vs 361 +/- 127 mmol/l, p greater than 0.05. However, the levels of five individual patients decreased after pirenzepine administration. We conclude that oral pirenzepine administration at this dose does not modify GH secretion nor improve short term metabolic control of the disease in young insulin-dependent diabetics. Further investigation, using higher doses and for a more prolonged period of time, is necessary to know the long term effects of this treatment.
Ruibal Francisco
J L
JL
Departamento de Pediatría, Hospital Universitario San Carlos, Madrid.
Seara Aguilar
G
G
Fernández Méndez
M
M
Noya Beiroa
E
E
Reverte Blanc
F
F
Valor García
S
S
Cabranes Díaz
J A
JA
Casado de Frías
E
E
D000284:Administration, Oral; D000293:Adolescent; D002648:Child; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D013006:Growth Hormone / Q000378:metabolism; D013007:Growth Hormone-Releasing Hormone / Q000032:analysis; D006801:Humans; D008297:Male; D010890:Pirenzepine / Q000008:administration & dosage*; D012636:Secretory Rate
D010890:Pirenzepine; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone
Uso de pirenzepina oral nocturna en jóvenes diabéticos insulino-dependientes.